Phase I Study of Concurrent Chemoradiotherapy With Weekly Cisplatin and Paclitaxel Chemotherapy for Locally Advanced Cervical Carcinoma in Japanese Women

2009 ◽  
Vol 19 (4) ◽  
pp. 723-727 ◽  
Author(s):  
Kenji Umayahara ◽  
Nobuhiro Takeshima ◽  
Takayuki Nose ◽  
Kiyoshi Fujiwara ◽  
Yuko Sugiyama ◽  
...  
Keyword(s):  
Phase I ◽  
Cervical Carcinoma ◽  
Phase I Study ◽  
Concurrent Chemoradiotherapy ◽  
Locally Advanced ◽  
Japanese Women ◽  
Advanced Cervical Carcinoma ◽  
Weekly Cisplatin

scholarly journals A phase I–II study of weekly cisplatin and gemcitabine with concurrent radiotherapy in locally advanced cervical carcinoma

2003 ◽  
Vol 14 (8) ◽  
pp. 1285-1290 ◽  
Author(s):  
J.J. Zarbá ◽  
A.V. Jaremtchuk ◽  
P. Gonzalez Jazey ◽  
M. Keropian ◽  
R. Castagnino ◽  
...  
Keyword(s):  
Phase I ◽  
Cervical Carcinoma ◽  
Locally Advanced ◽  
Concurrent Radiotherapy ◽  
Advanced Cervical Carcinoma ◽  
Weekly Cisplatin

Audiological findings in a Phase I protocol investigating the effect of WR 2721, high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma

1995 ◽  
Vol 109 (8) ◽  
pp. 744-747 ◽  
Author(s):  
John S. Rubin ◽  
Scott Wadler ◽  
Jonathan J. Baitler ◽  
Hilda Haynes ◽  
Alla Rozenblet ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Phase I ◽  
Cervical Carcinoma ◽  
Locally Advanced ◽  
Hearing Threshold ◽  
High Dose ◽  
High Frequencies ◽  
Advanced Cervical Carcinoma ◽  
Before And After ◽  
Audiologic Testing

AbstractWR 2721 (ethiofos) protects against the toxic effects of the heavy metal compound cisplatin. which is used in the treatment of solid tumours. In a Phase I protocol designed to determine the maximum dose of WR 2721 which could be tolerated when administered in combination with cisplatin and radiation therapy to patients with cervical carcinoma. 11 patients were evaluated by audiologic testing before and after cisplatin WR 2721 administration in an attempt to identify the degree of ototoxicity. Forty-five per cent were noted to have significant hearing threshold changes. predominantly in the high frequencies. There were no significant changes in the speech frequencies in this series. This contrasts with the greater degrees of ototoxicity observed in controls treated in the same way who received cisplatin without WR 2721 protection.

scholarly journals Weekly versus triweekly cisplatin-based concurrent chemoradiotherapy in the treatment of locally advanced cervical carcinoma

Medicine ◽  
2020 ◽  
Vol 99 (1) ◽  
pp. e18663
Author(s):  
Jiahao Zhu ◽  
Zheng Zhang ◽  
Dongyan Bian ◽  
Qingqing Chen ◽  
Qunchao Hu ◽  
...  
Keyword(s):  
Cervical Carcinoma ◽  
Concurrent Chemoradiotherapy ◽  
Locally Advanced ◽  
Advanced Cervical Carcinoma

Importance of duration of radiotherapy (RT) in patients (pts) with locally advanced cervical carcinoma (LACC) treated with concurrent chemoradiotherapy

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 16576-16576
Author(s):  
J. J. Zarba ◽  
F. R. Solórzano ◽  
P. Gonzalez Jasey ◽  
L. De Gregorio ◽  
R. Zelaya ◽  
...  
Keyword(s):  
Cervical Carcinoma ◽  
Concurrent Chemoradiotherapy ◽  
Locally Advanced ◽  
Advanced Cervical Carcinoma

Phase I–II Trial of Preoperative Chemoradiation in Locally Advanced Cervical Carcinoma

2000 ◽  
Vol 78 (3) ◽  
pp. 324-328 ◽  
Author(s):  
Salvatore Mancuso ◽  
Daniela Smaniotto ◽  
Pierluigi Benedetti Panici ◽  
Barbara Favale ◽  
Stefano Greggi ◽  
...  
Keyword(s):  
Phase I ◽  
Cervical Carcinoma ◽  
Locally Advanced ◽  
Preoperative Chemoradiation ◽  
Advanced Cervical Carcinoma

scholarly journals The Influence of Cisplatin Dose upon Survival in Concurrent Chemoradiotherapy of Locally Advanced Cervical Carcinoma with Weekly Cisplatin

2008 ◽  
Vol 51 (2) ◽  
pp. 95-99 ◽  
Author(s):  
Igor Sirák ◽  
Jiří Petera ◽  
Zdeněk Zoul
Keyword(s):  
Overall Survival ◽  
Cervical Carcinoma ◽  
Concurrent Chemoradiotherapy ◽  
Locally Advanced ◽  
Disease Free Survival ◽  
Hematological Toxicity ◽  
High Dose ◽  
Free Survival ◽  
Disease Free ◽  
Weekly Cisplatin

The objective of this study was to evaluate the influence of cisplatin dose upon 3-year overall and disease-free survival rate of patients with advanced cervical cancer treated with concurrent chemoradiotherapy with weekly cisplatin. Seventy-three patients with stage IIB – IVA cervical carcinoma were treated with pelvic (or pelvic + paraaortic) externalbeam radiotherapy, high-dose rate brachytherapy and concomitant chemotherapy with weekly cisplatin of 40 mg/m2 in the time period form January 2000 to December 2006 at our department. The 3-year overall survival and disease-free suvival rates were evaluated with regard to the number of cisplatin cycles applied during the external radiotherapy. Only twentyeight patients received the intended five doses of chemotherapy. The most frequent cause of chemotherapy delay was the acute hematological toxicity with leukopenia. The 3-year overall survival was 71 % and the 3-year disease-free survival was 61 %. Survival analyses didn’t prove a statistically significant influence of cisplatin dose upon 3-year survival in cervical carcinoma patients treated by exclusive chemoradiation with weekly cisplatin.

Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 523-523
Author(s):  
Suguru Yamada ◽  
Tsutomu Fujii ◽  
Nao Takano ◽  
Hideki Takami ◽  
Masaya Suenaga ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Phase I ◽  
Disease Control ◽  
Phase I Study ◽  
Concurrent Chemoradiotherapy ◽  
Locally Advanced ◽  
Disease Control Rate ◽  
Conversion Surgery ◽  
Level 3 ◽  
Grade 3

523 Background: Gemcitabine plus nab-paclitaxel (GnP) treatment is recommended for metastatic pancreatic adenocarcinoma (PDAC), and has been widely spread in our clinics. However, the usefulness for the patients with locally advanced PDAC is still controversial. We designed the phase I study to assess the toxicity and decide the recommended dose based on dose-limiting toxicity (DLT) of concurrent chemoradiotherapy using GnP for unresectable locally advanced (UR-LA) PDAC. Methods: UR-LA PDAC patients were enrolled in this clinical trial. The patients received the GnP on days 1, 8 and 15 every 28 days, and the cycles were repeated until PD. The patients were scheduled to receive gemcitabine (mg/m2) and nab-paclitaxel (mg/m2) at 5 dose levels: 400/75 (level 0), 600/75 (level 1), 600/100 (level 2), 800/100 (level 3) and 800/125 (level 4). Radiation therapy was delivered as a total dose of 50.4 Gy in 28 fractions, 1.8Gy per day. DLT was defined as grade 4 leucopenia or neutropenia ≥ 3 days, grade 3 neutropenia with fever ≥ 38℃, grade 3 or 4 thrombopenia, grade 3 non-hematological toxicity and > 14 days delay of treatment. Response and disease control rate, safety, adverse events, PFS and OS were evaluated. Results: Twelve patients were enrolled in this study. Treatment was well tolerated, and every 12 patients completed radiotherapy of 50.4 Gy. Our recommended dose was level 3, gemcitabine 800 mg/m2 and nab-paclitaxel 100 mg/m2. One patient experienced the DLT. The response rate was 41.7% and disease control rate was 75% (PR: 5, SD: 4, PD: 3). Median OS was 9.0 months. Among 12 patients, 6 (50%) patients underwent conversion surgery, and the pathological CR was observed in 2 patients. Conclusions: The concurrent chemoradiotherapy using GnP for UR-LA PDAC can be delivered safely and the high rate of conversion surgery was observed in our clinical trial. Based on this results, we will proceed the phase-II study. Clinical trial information: UMIN000020475.

Sign in / Sign up

Export Citation Format

Share Document